Provided by Tiger Trade Technology Pte. Ltd.

INSILICO

51.900
+1.4002.77%
Volume:11.19M
Turnover:576.31M
Market Cap:30.26B
PE:-11.58
High:52.850
Open:49.400
Low:49.260
Close:50.500
52wk High:80.900
52wk Low:29.980
Shares:583.00M
HK Float Shares:583.00M
Volume Ratio:0.60
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.480
ROE:--
ROA:-1.36%
PB:7.05
PE(LYR):-11.58
PS:28.56

Loading ...

Movement Alert|Insilico Medicine Falls 11.12% in Regular Trading, Massive Lock-up Share Expiry Triggers Concentrated Selling Pressure

Market Focus
·
Jun 30

Movement Alert|Insilico Medicine Falls 5.7% in Regular Trading, Selling Pressure Intensifies Ahead of Massive Lock-Up Expiry

Market Focus
·
Jun 29

Movement Alert|Insilico Medicine Falls 5.76% in Regular Trading, Profit-Taking Intensifies Ahead of Massive Lock-Up Expiry

Market Focus
·
Jun 26

Movement Alert|Insilico Medicine Rises 5.64% in Regular Trading, SK Biopharmaceuticals $2.5 Billion AI-Driven Collaboration Continues to Fuel Rally

Market Focus
·
Jun 25

Movement Alert|Insilico Medicine Rises 6.34% in Regular Trading, SK Biopharmaceuticals USD 2.5 Billion AI-Driven Collaboration Continues to Fuel Rally

Market Focus
·
Jun 24

Movement Alert|Insilico Medicine Rises 5.95% in Regular Trading, SK Biopharmaceuticals USD 2.5 Billion AI-Driven Collaboration Continues to Boost Sentiment

Market Focus
·
Jun 23

Hong Kong Stocks Decline on Renewed U.S.-China Friction; Shenzhen HQVT Technology Shines on Debut

MT Newswires Live
·
Jun 22

Shaers of Insilico Medicine Jump More Than 15% on SK Biopharmaceuticals Tie-up

THOMSON REUTERS
·
Jun 22

Insilico Medicine seals AI-driven neuroimmune R&D deal worth up to USD2.50 billion with SK Biopharmaceuticals

Bulletin Express
·
Jun 22

Insilico Partners with SK Biopharmaceuticals in AI-Powered Neuroscience Drug Discovery Deal Valued Up to $2.5 Billion

Stock News
·
Jun 22

BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders

Reuters
·
Jun 22

Insilico Medicine, SK Biopharmaceuticals enter AI drug R&D collaboration worth up to USD 2.5 billion

Reuters
·
Jun 22

Insilico Medicine Cayman Topco - and SK Biopharmaceuticals Enter AI-Powered R&D Collaboration Worth up to $2.5 Bln

THOMSON REUTERS
·
Jun 22

Insilico Medicine Cayman Topco - Total Potential Deal Value Exceeds $2.5 Bln Including Milestones and Royalties

THOMSON REUTERS
·
Jun 22

Insilico Medicine Cayman Topco - to Receive up to $18 Mln in Upfront and Near-Term Milestone Payments

THOMSON REUTERS
·
Jun 22

Movement Alert|Insilico Medicine Falls 5.06% in Regular Trading, Massive Lock-Up Expiry Countdown Suppresses Rebound Momentum

Market Focus
·
Jun 22

Insilico Shares Surge Nearly 14% on Inclusion in Key China Index Series, Following Multiple Major Index Additions

Stock News
·
Jun 18

Insilico Medicine's Stock Surges Over 6% Against Market Trend as Rentosertib Phase 3 Trial Meeting Commences

Stock News
·
Jun 18

Movement Alert|Insilico Medicine Rises 5.05% in Regular Trading, ISM8969 First-in-Human Dosing Milestone Catalyst Extends with Sector Tailwind

Market Focus
·
Jun 18

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven Nlrp3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration With Hygtia Therapeutics

THOMSON REUTERS
·
Jun 17